A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.

Background: Digoxin was found to inhibit prostate cancer (PCa) growth via the inhibition of HIF-1α synthesis in a mouse model. We hypothesized that a therapeutic dose of digoxin could inhibit human PCa growth and disease progression.

Methods: An open label, single arm pilot study was performed.